Advertisement

Indications for the presence of circulating peroxidized low density lipoproteins in WHHL rabbits treated with antioxidants

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Low density apolipoprotein (apo) B-100 in homozygous WHHL rabbits appears heterogeneous on SDS-PAGE. At least four high molecular weight apolipoproteins were identified in contrast to the uniform apo B-100 band in the very low density lipoprotein (VLDL) fraction of WHHL-homozygotes and the apo B containing lipoproteins present in WHHL heterozygotes or New Zealand White rabbits. We studied whether these abberations in homozygote WHHL-LDL were due to physical changes induced by lipid peroxidation. Therefore we treated WHHL rabbits for 28 days with a standard dose of 1% probucol or with a dose of 0.1% vitamin E and studied the parameters indicating lipid peroxidation in circulating LDL and in vitro in relation to its antioxidant content. The LDL of probucol-fed rabbits appeared completely resistant against oxidation in vitro with Cu2+ ions. LDL fluorescence and serum malondialdehyde concentrations, indicators of lipid peroxidized LDL, were lower than in the control WHHL rabbits. LDL of vitamin E-fed WHHL rabbits showed a twofold increased lag phase in comparison with LDL of control-fed animals; the maximal rate of oxidation was 2- to 3-fold lower while LDL fluorescence was between the values obtained in the two other groups. Malondialdehyde concentration in the vitamin E-treated group was also decreased when compared with controls. Despite these indications of increased lipid peroxidized circulating LDL in WHHL controls which could be reversed, at least partially, by the antioxidant treatments applied, these treatments were without effect on the physical structure of LDL as examined with agarose gel electrophoresis. Neither antioxidant treatment changed the typical apo B-100 pattern in WHHL-LDL.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Carew T.E.
        • Schwenke D.C.
        • Steinberg D.
        An antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks slowing down the progression of atherosclerosis in WHHL rabbits.
        in: 2nd Edn. Proc. Natl. Acad. Sci. USA. 84. 1987: 7725
        • Kita T.
        • Nagano Y.
        • Yokode M.
        • et al.
        Probucol prevents the progression of atherosclerosis in the WHHL rabbit, an animal model for familial hypercholesterolemia.
        in: 2nd Edn. Proc. Natl. Acad. Sci. USA. 84. 1987: 5928
        • Steinbrecher U.P.
        • Parthasarathy S.
        • Leake D.S.
        • Witztum J.L.
        • Steinberg D.
        Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids.
        in: 2nd Edn. Proc. Natl. Acad. Sci. USA. 81. 1984: 3883
        • Hendriksen T.
        • Mahoney E.M.
        • Steinberg D.
        Interactions of plasma lipoproteins with endothelial cells.
        Ann. N.Y. Acad. Sci. 1984; 401: 357
        • Morel D.W.
        • Dicorleto P.E.
        • Chisolm G.M.
        Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation.
        Arteriosclerosis. 1984; 4: 357
        • Steinberg D.
        • Parthasarathy S.
        • Carew T.W.
        • Khoo J.C.
        • Witztum J.L.
        Beyond cholesterol. Modifications of low density lipoprotein that increase its atherogenicity.
        N. Engl. J. Med. 1989; 320: 915
        • Esterbauer H.
        • Jürgens G.
        • Quehenberger O.
        • Koller E.
        Autooxidation of human low density lipoprotein: Loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes.
        J. Lipid Res. 1987; 28: 495
        • Esterbauer H.
        • Striegl G.
        • Puhl H.
        • Rotheneder M.
        Continuous monitoring of in vitro oxidation of human low density lipoprotein.
        Free Rad. Res. Commun. 1989; 6: 67
        • Esterbauer H.
        • Dieber-Rotheneder M.
        • Striegl G.
        • Waeg G.
        Role of vitamin E in preventing the oxidation of low-density lipoprotein.
        Am. J. Clin. Nutr. 1991; 53: 414S
        • Demacker P.N.M.
        • van Heijst P.J.
        • Stalenhoef A.F.H.
        A study of the chylomicron metabolism in WHHL rabbits after fat loading. Discrepancy between results based on measurement of apoprotein B-48 or retinyl palmitate.
        Biochem. J. 1992; 285: 641
        • Gustafson A.
        • Kane J.P.
        • Havel R.J.
        Determinants of kallikrein proteolysis of apolipoprotein B-100 in human blood plasma.
        Eur. J. Clin. Invest. 1988; 18: 75
        • Demacker P.N.M.
        • Vos-Janssen H.E.
        • Jansen A.P.
        • van't Laar A.
        Evaluation of the dual precipitation method by comparison with the ultracentrifugation method for measurement of lipoproteins in serum.
        Clin. Chem. 1977; 23: 1238
        • de Graaf J.
        • Hak-Lemmers H.L.M.
        • Hectors M.P.C.
        • Demacker P.N.M.
        • Hendriks J.C.M.
        • Stalenhoef A.F.H.
        Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects.
        Arterioscler. Thromb. 1991; 11: 298
        • Conti M.
        • Moraud P.C.
        • Levillain P.
        • Lemonnier A.
        Improved fluorometric determination of malondialdehyde.
        Clin. Chem. 1991; 37: 1273
        • Demacker P.N.M.
        • Hijmans A.G.M.
        • Stalenhoef A.F.H.
        • van't Laar A.
        Studies on the function of hepatic lipase in the cat after immunological blockade of the enzyme in vivo.
        Atherosclerosis. 1988; 69: 173
        • Lowry O.H.
        • Rosebrough N.J.
        • Farr A.L.
        • Randall R.J.
        Protein measurement with the Folin phenol reagent.
        J. Biol. Chem. 1951; 193: 265
        • Havel R.J.
        • Kita T.
        • Kotite L.
        • et al.
        Concentration and composition of lipoproteins in blood plasma of the WHHL rabbit. An animal model of human familial hypercholesterolemia.
        Arteriosclerosis. 1982; 6: 467
        • Stalenhoef A.F.H.
        • Kieinveld H.A.
        • Kosmeijer-Schuil T.G.
        • Demacker P.N.M.
        • Katan M.B.
        In vivo oxidised cholesterol in atherosclerosis.
        Atherosclerosis. 1993; 98: 113
        • Berliner A.B.
        • Territo M.C.
        • Sevanian A.
        • et al.
        Minimally modified low density lipoprotein stimulates monocyte endothelial interactions.
        J. Clin. Invest. 1990; 85: 1260
        • Rajavashisth T.B.
        • Andalibi A.
        • Territo M.C.
        • et al.
        Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified lowdensity lipoproteins.
        Nature. 1990; 344: 254
        • Harris R.S.
        • Gilmore III, H.R.
        • Bricker L.A.
        • Kiem I.M.
        • Rubin E.
        Long term oral administration of probucol [4,4′-(isopropylidenedithio)bis(2,6-di-t-butyl-phenol)] (DH-581) in the management of hypercholesterolemia.
        J. Am. Geriatr. Soc. 1974; 22: 167
        • Barker S.G.
        • Joffe B.I.
        • Mendelsohn D.
        • Seftel H.C.
        Treatment of homozygous familial hypercholesterolemia with probucol.
        S. Afr. Med. J. 1982; 62: 7
        • Kuzuya M.
        • Kuzuya F.
        Probucol as an antioxidant and antiatherogenic drug.
        Free Rad. Biol. Med. 1993; 14: 67
        • Williams R.J.
        • Motteram J.M.
        • Sharp C.H.
        • Gallagher P.J.
        Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits.
        Atherosclerosis. 1992; 94: 153